Journal of Clinical and Experimental Hematopathology

Scope & Guideline

Catalyzing Global Collaboration in Hematopathology.

Introduction

Explore the comprehensive scope of Journal of Clinical and Experimental Hematopathology through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Journal of Clinical and Experimental Hematopathology in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1346-4280
PublisherJAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
Support Open AccessYes
CountryJapan
TypeJournal
Convergefrom 2006 to 2016, from 2019 to 2024
AbbreviationJ CLIN EXP HEMATOP / J. Clin. Exp. Hematop.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNAGOYA UNIV GRAD SCH MEDICINE, HIGH-TECHNOLOGY APPLICATION MEDICINE, CLINICAL PATHOPHYSI, NAGOYA 466-8550, JAPAN

Aims and Scopes

The Journal of Clinical and Experimental Hematopathology primarily focuses on advancing the understanding and treatment of hematologic malignancies. It serves as a platform for sharing innovative research findings, clinical experiences, and insights into the pathology of blood-related disorders, particularly lymphomas and leukemias.
  1. Hematologic Malignancies Research:
    The journal emphasizes research on various hematologic malignancies, including lymphomas, leukemias, and plasma cell disorders. It covers both clinical and experimental studies that contribute to the understanding of these diseases.
  2. Clinical Case Reports and Reviews:
    A significant portion of the journal includes case reports and literature reviews that provide insights into rare and complex cases, thereby enhancing clinical knowledge and guiding treatment strategies.
  3. Pathological Insights and Diagnostics:
    The journal highlights the importance of pathology in diagnosing hematologic disorders. It publishes studies focusing on histopathological evaluations, immunohistochemistry, and molecular techniques that assist in accurate diagnosis.
  4. Therapeutic Advances and Clinical Trials:
    Research on new therapeutic approaches, including novel drug treatments and clinical trial outcomes, is a core focus. The journal aims to disseminate findings that can influence treatment protocols and improve patient outcomes.
  5. Tumor Microenvironment and Immune Response:
    There is a growing emphasis on the role of the tumor microenvironment and immune interactions in hematologic diseases. The journal explores how these factors affect disease progression and treatment responses.
The Journal of Clinical and Experimental Hematopathology has been evolving, with several themes emerging as increasingly prominent in recent publications. This section outlines the trending and emerging scopes that reflect the current interests and advancements in the field.
  1. Precision Medicine and Targeted Therapies:
    There is a significant trend towards research focused on precision medicine and targeted therapies for hematologic malignancies. This includes studies on specific genetic mutations, biomarkers, and tailored treatment approaches that enhance efficacy and minimize toxicity.
  2. Immunotherapy and CAR T-cell Therapy:
    Immunotherapy, particularly CAR T-cell therapy, is gaining prominence in the journal's publications. Research exploring the mechanisms, efficacy, and safety of these therapies is increasingly relevant as they become standard treatment options for various hematologic cancers.
  3. Tumor Microenvironment Studies:
    Emerging themes related to the tumor microenvironment, including the interplay between tumor cells and immune cells, are becoming a focal point. This research is crucial for understanding disease progression and developing new therapeutic strategies.
  4. Patient-Centered Outcomes and Quality of Life:
    Research that addresses patient perspectives, treatment satisfaction, and quality of life is on the rise. This trend highlights the importance of incorporating patient-reported outcomes into clinical practice and research.
  5. Novel Biomarkers for Diagnosis and Prognosis:
    The discovery and validation of novel biomarkers for the diagnosis and prognosis of hematologic malignancies are increasingly featured. Such studies are essential for improving diagnostic accuracy and tailoring treatment strategies.

Declining or Waning

While the Journal of Clinical and Experimental Hematopathology maintains a broad focus on hematologic disorders, certain themes have begun to decline in prominence. This section highlights these waning scopes based on recent publication trends.
  1. Basic Laboratory Techniques:
    There appears to be a declining focus on basic laboratory techniques and methodologies compared to more advanced and specialized studies. Research that centers solely on traditional laboratory methods without novel insights or applications has become less common.
  2. Generalized Reviews without Novel Insights:
    The journal has seen a decrease in generalized review articles that do not provide new perspectives or significant updates on existing knowledge. There is a trend towards more focused reviews that address specific questions or emerging issues.
  3. Older Treatment Protocols:
    Research centered around older treatment protocols, especially those that have been largely replaced by newer regimens or therapies, is becoming less frequent. The journal is shifting towards studies that investigate contemporary treatment strategies and their outcomes.
  4. Epidemiological Studies without Clinical Relevance:
    Epidemiological studies that lack direct clinical relevance or applicability to current treatment practices are being published less frequently. The focus is moving towards studies that bridge the gap between epidemiology and clinical application.

Similar Journals

International Journal of Laboratory Hematology

Advancing the science of hematology through innovative research.
Publisher: WILEYISSN: 1751-5521Frequency: 6 issues/year

The International Journal of Laboratory Hematology, published by WILEY, serves as a vital resource in the field of hematology, delivering high-quality research findings and innovations within laboratory practices since its inception in 2007. This journal, accessible under Open Access options, showcases cutting-edge studies that span critical aspects of biochemistry and clinical laboratory methodologies. With a notable impact factor reflected in its Q2 and Q3 rankings across various categories—such as Biochemistry (medical) and Hematology—this journal stands out within the Scopus rankings, positioning itself within the 60th and 59th percentiles of its respective fields. Situated in the United Kingdom, the journal's objectives lie in disseminating pivotal research that enhances our understanding of hematological disorders and laboratory techniques, making it an essential tool for researchers, professionals, and students alike who are committed to advancing the science of laboratory hematology and its applications.

LEUKEMIA & LYMPHOMA

Elevating the standards of hematological research.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

SEMINARS IN HEMATOLOGY

Driving Excellence in Hematology Education and Practice.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0037-1963Frequency: 4 issues/year

SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.

Blood Research

Innovating Insights into Blood Disorders and Treatments
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

ENDOCRINE PATHOLOGY

Elevating Standards in Endocrine Medicine
Publisher: HUMANA PRESS INCISSN: 1046-3976Frequency: 4 issues/year

ENDOCRINE PATHOLOGY is a premier journal published by HUMANA PRESS INC, dedicated to advancing the understanding of endocrine disorders through innovative research and clinical practices. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories such as Endocrinology, Diabetes and Metabolism, as well as Pathology and Forensic Medicine, this journal serves as a pivotal resource for researchers and professionals in the field. The journal covers a broad spectrum of topics related to endocrine pathology, providing insights into mechanisms, diagnostics, and therapeutics that inform both clinical and laboratory practices. Although it does not offer open access, its rigorous peer-review process ensures the dissemination of high-quality, impactful research that shapes clinical strategies and enhances patient care. With distribution spanning from its inception in 1990 to 2024, ENDOCRINE PATHOLOGY stands at the forefront of endocrine research, making it an essential read for anyone involved in the study and treatment of endocrine disorders.

Journal of Hematology & Oncology

Pioneering Discoveries in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Hematology Transfusion and Cell Therapy

Empowering discoveries in transfusion medicine.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Turkish Journal of Pathology

Elevating Standards in Pathology Research and Practice
Publisher: FEDERATION TURKISH PATHOLOGY SOCISSN: 1018-5615Frequency: 3 issues/year

Turkish Journal of Pathology, published by the Federation Turkish Pathology Society, stands as a vital platform for disseminating high-quality research in the field of pathology and forensic medicine. With an ISSN of 1018-5615 and an E-ISSN of 1309-5730, this journal has been an open-access publication since 2013, ensuring that cutting-edge findings are readily available to the global community. Based in Turkey, it aims to contribute significantly to the advancement of pathology as it converges from 2010 to 2024, currently holding a Q3 quartile ranking in its category according to 2023 metrics. As it ranks #129 out of 208 in the Scopus database for Medicine, Pathology, and Forensic Medicine, it offers researchers, professionals, and students invaluable insights and innovative studies that address critical developments in the field. The Turkish Journal of Pathology fosters collaboration and knowledge-sharing, making it an essential resource for anyone involved in pathology research and practice.

PATHOLOGY INTERNATIONAL

Exploring the Depths of Pathological Science
Publisher: WILEYISSN: 1320-5463Frequency: 12 issues/year

PATHOLOGY INTERNATIONAL, published by WILEY, stands as a distinguished journal in the field of pathology and forensic medicine, serving as an essential resource for researchers, clinicians, and students alike. With its ISSN 1320-5463 and E-ISSN 1440-1827, PATHOLOGY INTERNATIONAL has established itself since its inception in 1951, navigating through an evolving landscape in medical science with insights and breakthroughs up to 2024. It holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pathology and Forensic Medicine categories, indicating its robust influence and quality within these fields, as evidenced by its placement in the 70th percentile of Scopus rankings. While currently not an open-access journal, it provides access options that ensure valuable research remains available to the academic community. PATHOLOGY INTERNATIONAL commits to advancing the discipline through pioneering research articles, comprehensive reviews, and expert opinions that push the boundaries of understanding in pathology, thereby supporting the enhancement of diagnostic and therapeutic practices.

Hematology

Exploring Blood Science: Bridging Knowledge and Practice
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.